title: The disconnect between a national tuberculosis drug resistance survey and treatment outcomes: a lost opportunity.
abstract: We linked results from the Fourth Botswana National Drug Resistance Survey (DRS), 2007-2008, to patient records from the national Electronic Tuberculosis Registry to determine treatment outcomes. Of 915 new patients, 651 (71%) had treatment data available. Completion or cure was achieved for 10/15 (67%, 95%CI 42-85) with isoniazid monoresistance, (6/16, 38%, 95%CI 18-61) with multidrug resistance, while 73% (391/537, 95%CI 69-76) were susceptible to first-line drugs. The analysis was limited because of unavailable treatment records and undocumented outcomes. Prospective analyses following DRSs should be considered to ensure adequate outcome data.
authors.affiliation: Division of Tuberculosis Elimination, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
authors.forename: E S
authors.initials: ES
authors.lastname: Click
authors.affiliation: Botswana National Tuberculosis Program, Gaborone, Botswana.
authors.forename: J
authors.initials: J
authors.lastname: Chirenda
authors.affiliation: Botswana National Tuberculosis Program, Gaborone, Botswana.
authors.forename: S
authors.initials: S
authors.lastname: Kibias
authors.affiliation: Division of Tuberculosis Elimination, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
authors.forename: H J
authors.initials: HJ
authors.lastname: Menzies
authors.affiliation: Division of Tuberculosis Elimination, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
authors.forename: J E
authors.initials: JE
authors.lastname: Oeltmann
authors.affiliation: Botswana National Tuberculosis Program, Gaborone, Botswana.
authors.forename: C
authors.initials: C
authors.lastname: Sentle
authors.affiliation: National Tuberculosis Reference Laboratory, Gaborone, Botswana.
authors.forename: T
authors.initials: T
authors.lastname: Muribe
authors.affiliation: Botswana National Tuberculosis Program, Gaborone, Botswana.
authors.forename: T D
authors.initials: TD
authors.lastname: Lere
authors.affiliation: US Centers for Disease Control and Prevention-Botswana, Gaborone, Botswana.
authors.forename: R
authors.initials: R
authors.lastname: Makombe
authors.affiliation: Division of Tuberculosis Elimination, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
authors.forename: S
authors.initials: S
authors.lastname: Bamrah
authors.affiliation: Division of Tuberculosis Elimination, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
authors.forename: B K
authors.initials: BK
authors.lastname: Moore
authors.affiliation: Division of Tuberculosis Elimination, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
authors.forename: K P
authors.initials: KP
authors.lastname: Cain
mesh_terms: D000995:Antitubercular Agents / Q000494:pharmacology*; D001902:Botswana; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007538:Isoniazid / Q000494:pharmacology*; D008297:Male; D009169:Mycobacterium tuberculosis / Q000187:drug effects* / Q000302:isolation & purification; D012042:Registries; D012189:Retrospective Studies; D016896:Treatment Outcome; D018088:Tuberculosis, Multidrug-Resistant / Q000188:drug therapy* / Q000382:microbiology
chemical_list: D000995:Antitubercular Agents; D007538:Isoniazid